NCT06907082View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice

NACompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

December 28, 2020

Primary Completion Date

March 14, 2024

Study Completion Date

March 14, 2024

Conditions
Breast Cancer
Interventions
DRUG

Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.

Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.

Trial Locations (1)

30120

HCUVA, Murcia

All Listed Sponsors
lead

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia

OTHER

NCT06907082 - Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice | Biotech Hunter | Biotech Hunter